Online inquiry

IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3266MR)

This product GTTS-WQ3266MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Lombar radicular pain research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3266MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15447MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ1112MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ10683MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ15522MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ2438MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ13112MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ587MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ12197MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MORAb-022
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW